Please login to the form below

Not currently logged in
Email:
Password:

Roche reshuffles its executive committee, again

Sophie Kornowski-Bonnet joins Reed and heads for the exit

James SabryJames Sabry is set to take the helm of Roche’s deal-making business from 1 August, following the imminent departure of Roche’s current head of partnering Sophie Kornowski-Bonnet.

She leaves to ambiguously pursue “other opportunities” according to the Swiss drug maker, who received similar news just two months ago when its head of Pharma Research and Early Development (pRED) John Reed left to join rival Sanofi as its head of research and development.

Sabry however, – who has ample experience striking deals in the US biotech scene – joins from Roche’s blockbuster-producing arm Genentech as its senior vice president.

Genentech was acquired by Roche back in 2009 for a whopping $46.8bn and since then opened the biggest biotech factory in the world, which is based in California, US.

Under Sabry (pictured), Genentech has seen through a number of deals, most recently signing a $1bn drug discovery alliance with Lodo Therapeutics to research genomes of microbes in soil.

As Roche’s global head of partnering however, Sabry’s new role will combine the partnering functions across the business, simultaneously becoming a member of the corporate executive committee.

Roche’s chief executive Severin Schwan said: “James brings a wealth of medical, scientific and business development expertise to successfully identify the best external innovation opportunities and bring them into the Roche Group.”

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.

Article by
Gemma Jones

22nd June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics